Re dual pci study

Dual Antithrombotic Therapy with Dabigatran after PCI in ...

★ ★ ☆ ☆ ☆

Cannon CP, Gropper S, Bhatt DL, et al. Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy ...

Dual Antithrombotic Therapy with Dabigatran after PCI in ...

Design and Rationale of the RE-DUAL PCI Trial: A ...

★ ★ ★ ★ ★

Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.

Design and Rationale of the RE-DUAL PCI Trial: A ...

RE-DUAL PCI study on dabigatran in AF patients after PCI

★ ★ ☆ ☆ ☆

11/11/2016 · Patient enrolment completed for RE-DUAL PCI ™ study assessing dabigatran in atrial fibrillation patients after PCI with stenting. Over 2,700 atrial fibrillation (AF) patients undergoing a percutaneous coronary intervention (PCI) with stenting randomised in RE-DUAL PCI ™ study 1; First PCI study to evaluate the safety of a dual versus triple antithrombotic regimen using NOAC dosages …

RE-DUAL PCI study on dabigatran in AF patients after PCI

Design and Rationale of the RE‐DUAL PCI Trial: A ...

★ ★ ★ ☆ ☆

8/26/2016 · The RE‐DUAL PCI trial aims to study several new strategies for antithrombotic treatment in these patients, and 3 regimens across the spectrum of intensity have been selected. The 2 dual antithrombotic therapy regimens will include a NOAC—dabigatran etexilate—at both of the doses shown to be effective and approved (worldwide).

Design and Rationale of the RE‐DUAL PCI Trial: A ...

RE-DUAL PCI™ trial data presented at ESC 2017 | Press

★ ★ ☆ ☆ ☆

“The results we have seen from RE-DUAL PCI ™ are another great piece of evidence on the benefit Pradaxa ® can offer patients with atrial fibrillation and their treating physicians; a benefit which has been shown in many situations along the treatment journey,” commented Professor Jörg Kreuzer, Vice President Medicine, Therapeutic Area Cardiovascular, Boehringer Ingelheim.

RE-DUAL PCI™ trial data presented at ESC 2017 | Press

Evaluation of Dual Therapy With Dabigatran vs. Triple ...

★ ★ ★ ★ ★

6/17/2014 · Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators.

Evaluation of Dual Therapy With Dabigatran vs. Triple ...

Poll: RE-DUAL PCI Study - American College of Cardiology

★ ★ ★ ★ ★

9/11/2017 · As revealed during the 2017 European Society of Cardiology Congress, the RE-DUAL PCI (Randomized Evaluation of Dual Antithrombotic Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) study ...

Poll: RE-DUAL PCI Study - American College of Cardiology

RE-DUAL PCI: dual antithrombotic therapy with dabigatran ...

★ ★ ★ ☆ ☆

RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibrillation Christopher P. Cannon Deepak L Bhatt, Jonas Oldgren, Gregory YH Lip, Stephen G Ellis, Takeshi Kimura, Michael Maeng, ... *Study drug should be administered 6 hours after sheath removal and no later than ≤120 ...

RE-DUAL PCI: dual antithrombotic therapy with dabigatran ...

in Atrial Fibrillation - nejm.org

★ ★ ☆ ☆ ☆

tervention (RE-DUAL PCI) trial is pro-vided in the Supplementary Appendix, available with the full text of this article at NEJM.org. This article was published on August 27,

in Atrial Fibrillation - nejm.org

RE-DUAL PCI - Dabigatran-based dual antithrombotic regimen ...

★ ★ ★ ★ ☆

8/30/2017 · Cannon CP, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. NEJM 2017 Bottom line: RE-DUAL PCI provides further evidence supporting dual therapy with an oral anticoagulant + P2Y12 inhibitor in patients with AF post-PCI instead of triple therapy. Dual

RE-DUAL PCI - Dabigatran-based dual antithrombotic regimen ...

RE-DUAL PCI: Testing Triple and Dual Therapy ... - Medscape

★ ★ ★ ★ ★

Dr Chris Cannon describes the RE-DUAL PCI trial, which will test triple vs dual therapy in patients with AF undergoing PCI. ... The problem is that it was just a 600-patient study, so we are ...

RE-DUAL PCI: Testing Triple and Dual Therapy ... - Medscape

Enrollment completed for RE-DUAL PCI study of 2,700 atrial ...

★ ★ ★ ★ ★

11/14/2016 · The Baim Institute has announced that patient enrollment into the international Phase IIIb RE-DUAL PCI study is complete. The study evaluates …

Enrollment completed for RE-DUAL PCI study of 2,700 atrial ...

New RE-DUAL PCI Data: Dabigatran Dual Therapy Benefit ...

★ ★ ★ ☆ ☆

The "reassuring" findings from the RE-DUAL PCI study were seen in several subgroups of patients with atrial fibrillation in a setting where they face an excess risk of bleeding with current triple ...

New RE-DUAL PCI Data: Dabigatran Dual Therapy Benefit ...

Dual Antithrombotic Approach in Patients With A-fib ...

★ ★ ☆ ☆ ☆

8/27/2017 · BARCELONA, Spain—The benefit of moving away from traditional triple antithrombotic therapy for patients with A-fib who have undergone PCI has been underscored further in the RE-DUAL PCI trial. The study showed that combining one of two dabigatran doses with a …

Dual Antithrombotic Approach in Patients With A-fib ...

Enrollment completed for RE-DUAL PCI study of 2,700 atrial ...

★ ★ ★ ☆ ☆

Enrollment completed for RE-DUAL PCI study of 2,700 atrial fibrillation patients 14 November 2016 The Baim Institute has announced that patient enrollment into the international Phase IIIb RE-

Enrollment completed for RE-DUAL PCI study of 2,700 atrial ...

Subgroup Analysis from the RE-DUAL PCI Trial

★ ★ ★ ★ ☆

Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with Dabigatran in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan H. Hohnloser, Gregory Y. H. Lip, Stephen G. Ellis, Takeshi Kimura,

Subgroup Analysis from the RE-DUAL PCI Trial

Dabigatran dual therapy with ticagrelor or clopidogrel ...

★ ★ ★ ★ ☆

The detailed design and primary results of RE-DUAL PCI have been published (RE-DUAL PCI ClinicalTrials.gov number, NCT02164864). 16, 17 Men and women who were at least 18 years of age were eligible for inclusion if they had non-valvular AF and had been successfully treated with PCI with a bare-metal or drug-eluting stent within the prior 120 h ...

Dabigatran dual therapy with ticagrelor or clopidogrel ...

Triple Therapy After PCI in AF: A Quagmire Soon to be Drained

★ ★ ★ ★ ☆

concomitant ACS or undergoing PCI are ongoing RE-DUAL PCI (dabigatran) 2,500 NVAF patients with ACS or PCI AUGUSTUS (apixaban) 4,600 NVAF patients with ACS or PCI Primary objective: To assess the safety of two rivaroxaban treatment strategies vs the combination of VKA with DAPT

Triple Therapy After PCI in AF: A Quagmire Soon to be Drained

RE-DUAL PCI Trial: DAPT with Dabigatran after PCI in AF

★ ★ ★ ★ ★

RE-DUAL PCI trial was a multi-center, randomized trial that compared the outcomes of triple and dual therapy as well as warfarin and dabigatran. Patients with AF who have undergone PCI (N=2,725) were randomly assigned to either triple therapy (aspirin, warfarin and a P2Y12 inhibitor) or dual therapy (dabigatran 150mg BD or 110mg BD and a P2Y12 ...

RE-DUAL PCI Trial: DAPT with Dabigatran after PCI in AF

Patient enrolment completed for RE-DUAL PCI™ study ...

★ ★ ★ ★ ☆

11/11/2016 · INGELHEIM, Germany--(BUSINESS WIRE)--Patient enrolment into the international Phase IIIb RE-DUAL PCI ™ study is complete. 1 The study evaluates the safety and efficacy of …

Patient enrolment completed for RE-DUAL PCI™ study ...

Enrollment Completed for RE-DUAL PCI™ Study of 2,700 ...

★ ★ ★ ★ ★

The Baim Institute has announced that patient enrollment into the international Phase IIIb RE-DUAL PCI™ study is complete. The study evaluates the safety and efficacy of dabigatran etexilate in atrial fibrillation (AF) patients undergoing a percutaneous coronary intervention (PCI) with stent placement.

Enrollment Completed for RE-DUAL PCI™ Study of 2,700 ...

Safety and efficacy of non–vitamin K oral anticoagulant ...

★ ★ ★ ☆ ☆

C.P. Cannon, S. Gropper, D.L. Bhatt, et al.Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary ...

Safety and efficacy of non–vitamin K oral anticoagulant ...

RE-DUAL PCI: Dual therapy beneficial in all subgroups in ...

★ ★ ★ ★ ☆

11/17/2017 · RE-DUAL PCI: Dual therapy beneficial in all subgroups in PCI with AF ... The interaction P values weren’t significant in RE-DUAL PCI, ... but consistent with overall results of the study for ...

RE-DUAL PCI: Dual therapy beneficial in all subgroups in ...

Enrollment completed for RE-DUAL PCI™ study of 2,700 ...

★ ★ ★ ★ ★

11/14/2016 · The Baim Institute announces that patient enrollment into the international Phase IIIb RE-DUAL PCI™ study is complete. The study evaluates the safety and efficacy of dabigatran etexilate ...

Enrollment completed for RE-DUAL PCI™ study of 2,700 ...

The effect of PCI complexity on the efficacy and safety of ...

★ ★ ★ ☆ ☆

The Dual AntiPlatelet Therapy (DAPT) Study has shown that the angiographic lesion complexity, or clinical complexity – including acute coronary syndrome (ACS) presentation, were associated with increased risk of ischaemic events after PCI. Aim: This subgroup analysis of RE-DUAL assessed the treatment effects on bleeding and thromboembolic ...

The effect of PCI complexity on the efficacy and safety of ...

AF and PCI in Practice - Medscape

★ ★ ★ ☆ ☆

RE-DUAL PCI Study Design. RE-DUAL PCI Primary Endpoint: Time to First Bleeding Event. RE-DUAL PCI: Rates of TIMI Major Bleeding. RE-DUAL PCI: Rate of Intracranial Hemorrhage. RE-DUAL PCI: Time to Death or Thromboembolic Event, or Unplanned Revascularization. RE-DUAL PCI: Additional Individual Thromboembolic Endpoints.

AF and PCI in Practice - Medscape

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and ...

★ ★ ★ ☆ ☆

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status. Presenter: Deepak L. Bhatt. November 01, 2016. REGISTER for free or LOG IN to view this content. Become a GOLD or PLATINUM member to access …

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and ...

Antiplatelet therapy in coronary artery disease

★ ★ ★ ☆ ☆

The RE-DUAL PCI study compared dabigatran + P2Y12 inhibitor to triple therapy with warfarin. It's not clear at this time what the net benefit (decreased risk of thrombotic events minus risk of bleeding) is with these combinations; The ACCP and the AHA both make …

Antiplatelet therapy in coronary artery disease

RE-DUAL PCI™ Results Offer Favorable New Safety Data on ...

★ ★ ★ ★ ☆

RE-DUAL PCI™ Results Offer Favorable New Safety Data on Pradaxa® - Large safety study compared dual therapy with Pradaxa® (dabigatran etexilate mesylate) to triple therapy with warfarin in ...

RE-DUAL PCI™ Results Offer Favorable New Safety Data on ...

Safety and efficacy of dual vs. triple antithrombotic ...

★ ★ ☆ ☆ ☆

About RE-DUAL PCI™ RE-DUAL ... The main objective of the study is to compare a dual antithrombotic therapy regimen of either 150mg or 110mg dabigatran etexilate mesylate twice daily plus ...

Safety and efficacy of dual vs. triple antithrombotic ...

RE-DUAL PCI™ Results Offer Favorable New Safety Data on ...

★ ★ ★ ☆ ☆

Patient enrolment into the international Phase IIIb RE-DUAL PCI ™ study is complete. 1 The study evaluates the safety and efficacy of dabigatran etexilate (marketed as Pradaxa ®) in atrial fibrillation (AF) patients undergoing a percutaneous coronary intervention (PCI) with stent placement. 2,3 ...

RE-DUAL PCI™ Results Offer Favorable New Safety Data on ...

Patient enrolment completed for RE-DUAL PCI™ study ...

★ ★ ☆ ☆ ☆

10/19/2017 · In the RE-DUAL PCI study, researchers compared the use of two regimens of dual antithrombotic therapy that included dabigatran with the use of triple antithrombotic therapy that included warfarin among patients with atrial fibrillation who had undergone percutaneous coronary intervention (PCI).

Patient enrolment completed for RE-DUAL PCI™ study ...

Dual antithrombotic therapy with dabigatran after PCI in ...

★ ★ ★ ★ ☆

Design and Rationale of the RE‐DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting

Dual antithrombotic therapy with dabigatran after PCI in ...

Design and Rationale of the RE‐DUAL PCI Trial: A ...

★ ★ ★ ★ ☆

RE-DUAL PCI - Cannon et al 2017 Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation.

Design and Rationale of the RE‐DUAL PCI Trial: A ...

RE-DUAL PCI - Cannon et al 2017

★ ★ ★ ★ ★

เปรียบเทียบ PIONEER AF-PCI กับ RE-DUAL PCI ใน 25 มุมมอง PIONEER AF presented in AHA 2016 RE-DUAL presented in ESC 2017 1. Background Knowledge ผู้ป่วย...

RE-DUAL PCI - Cannon et al 2017

1412 Cardiology - เปรียบเทียบ PIONEER AF-PCI กับ RE-DUAL ...

★ ★ ☆ ☆ ☆

The Baim Institute has announced that patient enrollment into the international Phase IIIb RE-DUAL PCI™ study is complete. The study evaluates the safety and efficacy of dabigatran etexilate in ...

1412 Cardiology - เปรียบเทียบ PIONEER AF-PCI กับ RE-DUAL ...

Baim Institute for Clinical Research: Enrollment Completed ...

★ ★ ★ ☆ ☆

Similar to PIONEER AF-PCI, RE-DUAL PCI was underpowered for efficacy endpoints, and the rates of the composite of all-cause death, MI, stroke or systemic embolism, or unplanned revascularization were similar across study groups . Questions regarding ticagrelor and prasugrel versus clopidogrel in …

Baim Institute for Clinical Research: Enrollment Completed ...

Triple Antithrombotic Therapy for Patients with Atrial ...

★ ★ ★ ☆ ☆

Materials related to Late Breaking Clinical Trials will be released after time of presentation. Sunday, Nov. 12. ... RE-DUAL PCI: Subgroup Analysis From the RE-DUAL PCI Trial: Dual Antithrombotic Therapy With Dabigatran in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention ... Results of the Study of a Tele-Pharmacy ...

Triple Antithrombotic Therapy for Patients with Atrial ...

SS17: Late Breaking Clinical Trials - Professional Heart Daily

★ ★ ★ ☆ ☆

RE-DUAL PCI: Thromboembolic Events, Death, or Unplanned Revascularization. PIONEER AF-PCIClinically Significant Bleeding . PIONEER AF-PCIStudy Design. PIONEER AF-PCIMACE. RE-DUAL PCITIMI Major Bleeding and ICH. Duration of Triple TherapyOptions. Optimal OAC DoseFull Dose vs …

SS17: Late Breaking Clinical Trials - Professional Heart Daily

The Challenge of AF and PCI: Practical Strategies to ...

★ ★ ★ ☆ ☆

Matias Nordaby currently works at the Clinical Development and Medical Affairs, Boehringer Ingelheim. Matias does research in Cardiology, Clinical Trials and Clinical Pharmacology. ... the RE-DUAL ...

The Challenge of AF and PCI: Practical Strategies to ...

Matias Nordaby | MD, Cardiologist | Boehringer Ingelheim ...

★ ★ ☆ ☆ ☆

RE-DUAL PCI 2,500 dabigatran* 02164864 bleeding AUGUSTUS** 4,600 apixaban/warfarin 02415400 bleeding Ongoing Trials in PCI for AFpatients with or without Aspirin * 150mg bid vs 110 mg bid **ACS with or without PCI only arm endpoint P2Y12 warfarin P2Y12 aspirin warfarin P2Y12 aspirin MANJUSRI2 296 warfarin warfarin 02206815 bleeding clopidogrel ...

Matias Nordaby | MD, Cardiologist | Boehringer Ingelheim ...

Stable CAD, Elective Stenting and AFib

★ ★ ☆ ☆ ☆

View This Abstract Online; Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.

Stable CAD, Elective Stenting and AFib

Design and Rationale of the RE-DUAL PCI Trial: A ...

★ ★ ★ ★ ★

Cannon CP, Gropper, Bhatt DL, et al. Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary ...

Design and Rationale of the RE-DUAL PCI Trial: A ...

NOACs, AF, and PCI: What Do the Latest Data Suggest ...

★ ★ ★ ☆ ☆

You have full text access to this OnlineOpen article Clinical Cardiology Volume 39, Issue 10, Version of Record online: 26 AUG 2016

NOACs, AF, and PCI: What Do the Latest Data Suggest ...

Design and Rationale of the RE-DUAL PCI Trial: A ...

★ ★ ★ ★ ★

8/20/2018 · “Insights from the RE-DUAL PCI TM and GLORIA TM-AF study data have helped to further inform the positive safety profile of dabigatran etexilate for the treatment of AF patients”, said Waheed ...

Design and Rationale of the RE-DUAL PCI Trial: A ...

Boehringer Ingelheim: New sub-analyses to be presented at ...

★ ★ ☆ ☆ ☆

11/11/2016 · Boehringer Ingelheim Release: Patient Enrollment Completed For RE-DUAL PCI Study Assessing Dabigatran In Atrial Fibrillation Patients After PCI With Stenting - read this article along with other careers information, tips and advice on BioSpace

Boehringer Ingelheim: New sub-analyses to be presented at ...

Boehringer Ingelheim Release: Patient Enrollment Completed ...

★ ★ ★ ☆ ☆

6/1/2018 · After study selection, two randomised controlled trials reporting early outcome data of patients with AF randomised to DOACs or VKAs and treated with antiplatelets after PCI. Data were collected from the two ad hoc trials, PIONEER AF-PCI and RE-DUAL PCI16 19 .

Boehringer Ingelheim Release: Patient Enrollment Completed ...

Direct oral anticoagulants versus standard triple therapy ...

★ ★ ★ ★ ☆

undefined

Direct oral anticoagulants versus standard triple therapy ...
Amosova-study-bible.html,Amr-research-study-plmc.html,Amy-wilcock-aga-bible-study.html,An-alcoholic-case-study.html,Analytical-numerical-empirical-study.html